{"meta":{"query_hash":"d4a2259a0084","filters":{"venue":"EMJ Cardiology"},"cohort_total":8,"direct_labels_cover":0,"predictions_cover":8,"exported":8,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/d4a2259a0084","api":"https://metacan.xera.ac/api/v1/cohort?venue=EMJ+Cardiology"},"results":[{"id":"W4312252639","doi":"10.33590/emjcardiol/10314431","title":"Blood Pressure Control: A Marathon or a Sprint?","year":2016,"lang":"en","type":"article","venue":"EMJ Cardiology","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Menarini Group; Alberta Innovates; Novo Nordisk; European Society of Cardiology; AstraZeneca; Daiichi Sankyo Europe; University of Alberta; Servier; Pfizer; Amgen","keywords":"Sprint; Blood pressure; Medicine; Control (management); League; Physical therapy; Management; Internal medicine","score_opus":0.024704529840826907,"score_gpt":0.2672023435846044,"score_spread":0.24249781374377746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312252639","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010283575,0.051546406,0.0005084429,0.7522514,0.19061743,0.000052294698,0.000031804422,0.00003420144,0.0039297296],"genre_scores_gemma":[0.0217128,0.11649895,0.0026230786,0.6260476,0.20539425,0.0002533646,0.00008560907,0.0001488904,0.027235415],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927908,0.0033698175,0.0007474402,0.00071841903,0.0013409731,0.0010324477],"domain_scores_gemma":[0.9881479,0.003921976,0.00059159717,0.0002447117,0.0025286896,0.004565124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0139023075,0.0019304014,0.0023113198,0.0013112169,0.0052977526,0.00851542,0.0023391964,0.013256468,0.012649259],"category_scores_gemma":[0.022886647,0.000772909,0.0024664244,0.0009229419,0.006305237,0.013446397,0.0070127686,0.027506236,0.003409339],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005365051,0.00038633595,0.0009915109,0.0025387905,0.00016829894,0.000533873,0.006257959,0.00010276876,0.00053361844,0.01446084,0.8332516,0.1402378],"study_design_scores_gemma":[0.0001687991,0.0008242153,0.0013898424,0.0044936347,0.000092099326,0.0006561689,0.008613238,0.00011261197,0.00017198741,0.008149326,0.97522265,0.000105358224],"about_ca_topic_score_codex":0.0022074434,"about_ca_topic_score_gemma":0.004886655,"teacher_disagreement_score":0.0139023075,"about_ca_system_score_codex":0.003694824,"about_ca_system_score_gemma":0.0057949033,"threshold_uncertainty_score":0.07352328},"labels":[],"label_agreement":null},{"id":"W4312275451","doi":"10.33590/emjcardiol/10313179","title":"European Society of Cardiology Chronic Coronary Syndromes Guidelines Review","year":2019,"lang":"en","type":"article","venue":"EMJ Cardiology","topic":"Acute Myocardial Infarction Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Regeneron Pharmaceuticals; Sanofi; Bayer; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline; Amgen","keywords":"Antithrombotic; Medicine; Guideline; Canadian Cardiovascular Society; Intensive care medicine; Coronary artery disease; Aspirin; Acute coronary syndrome; Internal medicine; Cardiology; Angina; Myocardial infarction; Pathology","score_opus":0.079249327475983,"score_gpt":0.3783335866916825,"score_spread":0.2990842592156995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312275451","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021575706,0.94254786,0.0006559737,0.022764541,0.0069638137,0.0003578318,0.0015626916,0.00011324851,0.024818253],"genre_scores_gemma":[0.0024950537,0.96456736,0.0024610742,0.013390439,0.005588556,0.0006268796,0.0042103953,0.000038940496,0.0066212984],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965276,0.0008509659,0.00090388657,0.00024380894,0.0012692541,0.0002044406],"domain_scores_gemma":[0.99092335,0.0026775817,0.0013803038,0.00014433378,0.004340128,0.00053437205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029908975,0.001204193,0.002248014,0.008045489,0.00080722204,0.0024271703,0.0020501874,0.0033744245,0.022685396],"category_scores_gemma":[0.014529133,0.00042322115,0.0016510786,0.0061371904,0.0005539226,0.0014200399,0.0014224281,0.002809592,0.010240349],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052800904,0.000041550324,0.00041352212,0.02287664,0.00015394535,0.000325856,0.000088231216,0.00013467493,0.00010912373,0.0022553117,0.6899745,0.2835738],"study_design_scores_gemma":[0.000078017256,0.00003468674,0.0015196669,0.045790188,0.0002841716,0.0009514364,0.000065356784,0.000059430728,0.000037435624,0.0014079628,0.94974947,0.000022268869],"about_ca_topic_score_codex":0.005320582,"about_ca_topic_score_gemma":0.010637902,"teacher_disagreement_score":0.022685396,"about_ca_system_score_codex":0.002478235,"about_ca_system_score_gemma":0.010155239,"threshold_uncertainty_score":0.07589024},"labels":[],"label_agreement":null},{"id":"W4312465804","doi":"10.33590/emjcardiol/10312045","title":"Reversal of Apixaban and Rivaroxaban Anticoagulation by Andexanet Alfa in ANNEXA-A and ANNEXA-R as Assessed by Non-Tissue Factor-Initiated Thrombin Generation Independent of Tissue Factor Pathway Inhibitor","year":2018,"lang":"en","type":"article","venue":"EMJ Cardiology","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Apixaban; Tissue factor; Rivaroxaban; Thrombin; Tissue factor pathway inhibitor; Pharmacology; Coagulation; Medicine; Hemostasis; Chemistry; Internal medicine; Atrial fibrillation; Warfarin; Platelet","score_opus":0.05492115250333404,"score_gpt":0.338456687234884,"score_spread":0.2835355347315499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312465804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848039,0.0100419605,0.0007164815,0.00068861176,0.0001301844,0.00006216388,0.00006204721,0.000029002753,0.003465612],"genre_scores_gemma":[0.9942373,0.0034001593,0.0005740257,0.00026307718,0.00009566091,0.000046985046,0.000112489404,0.000006591475,0.0012637317],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996418,0.0001345583,0.00004874801,0.000029303348,0.0000896632,0.000055989203],"domain_scores_gemma":[0.9997787,0.00004424811,0.0001015636,0.00002097397,0.000019059393,0.000035525612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006606514,0.00018390377,0.0005099815,0.00012789668,0.00011714778,0.00057686213,0.00018283182,0.00026472175,0.00094942964],"category_scores_gemma":[0.001033082,0.000064467655,0.0003536368,0.00012375905,0.0001981449,0.00028587476,0.00017142078,0.0008552574,0.00017211489],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08068378,0.0050951038,0.030735755,0.0011124009,0.001029249,0.0033239084,0.00048870285,0.0010081511,0.25602067,0.0032298667,0.005838544,0.61143386],"study_design_scores_gemma":[0.016762815,0.17733209,0.3652005,0.0007675046,0.0026490793,0.022144897,0.00072658464,0.0068115103,0.29789835,0.0032623224,0.106288865,0.00015537656],"about_ca_topic_score_codex":0.00015011197,"about_ca_topic_score_gemma":0.00022773215,"teacher_disagreement_score":0.00094942964,"about_ca_system_score_codex":0.00016424089,"about_ca_system_score_gemma":0.00026571497,"threshold_uncertainty_score":0.003493905},"labels":[],"label_agreement":null},{"id":"W4312725520","doi":"10.33590/emjcardiol/10312254","title":"Interpreting Findings with Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Collective Views on Data from Seminal Studies to Present in Clinical Practice","year":2016,"lang":"en","type":"article","venue":"EMJ Cardiology","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; Ionis Pharmaceuticals; Valeant Pharmaceuticals International; Sanofi; AstraZeneca; Daiichi-Sankyo; Pfizer; Bristol-Myers Squibb","keywords":"Rivaroxaban; Atrial fibrillation; Medicine; Warfarin; Vitamin K antagonist; Dabigatran; Stroke (engine); Apixaban; Internal medicine; Clinical trial; Anticoagulant; Intensive care medicine","score_opus":0.22266405471509015,"score_gpt":0.48112322845675126,"score_spread":0.2584591737416611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312725520","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008011246,0.34035686,0.010638003,0.61624557,0.0189028,0.00017559234,0.00020092307,0.00010954116,0.005359518],"genre_scores_gemma":[0.23427302,0.23322582,0.051194258,0.39977747,0.078643516,0.00079558016,0.00034120714,0.00046666,0.0012825314],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.5183737,0.2921823,0.091812775,0.023379497,0.07188296,0.0023686804],"domain_scores_gemma":[0.14532435,0.68251836,0.06680179,0.03428484,0.065310046,0.005760643],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.51771915,0.0016108934,0.0048505766,0.010751136,0.0045874706,0.024203246,0.009150511,0.014014304,0.0018509439],"category_scores_gemma":[0.6690875,0.0017174174,0.003554407,0.008787939,0.034653865,0.020793129,0.011633421,0.020603213,0.00090430584],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015133925,0.00032931042,0.07974037,0.05315925,0.012068597,0.002503264,0.057326302,0.0018234294,0.0025352293,0.07304699,0.1621914,0.5537625],"study_design_scores_gemma":[0.00085409015,0.0021862914,0.04949309,0.14554065,0.011453955,0.008937133,0.04404549,0.002280821,0.0041314145,0.25813025,0.47176954,0.0011771774],"about_ca_topic_score_codex":0.002853005,"about_ca_topic_score_gemma":0.0044136993,"teacher_disagreement_score":0.51771915,"about_ca_system_score_codex":0.007717873,"about_ca_system_score_gemma":0.014779047,"threshold_uncertainty_score":0.5947382},"labels":[],"label_agreement":null},{"id":"W4317927131","doi":"10.33590/emjcardiol/10312244","title":"The Changing Landscape in Oral Anticoagulation – The Last Pieces of the Puzzle","year":2013,"lang":"en","type":"article","venue":"EMJ Cardiology","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"Daiichi Sankyo Europe","keywords":"Geography; History; Aesthetics; Art","score_opus":0.009966062832287527,"score_gpt":0.23944290982992927,"score_spread":0.22947684699764176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317927131","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031907505,0.12821655,0.0011298866,0.85466117,0.0071744802,0.000010458017,0.00023436602,0.00006220881,0.005320084],"genre_scores_gemma":[0.08732314,0.4534648,0.004701825,0.39696592,0.04990106,0.00007854193,0.0005674429,0.00028638376,0.0067108627],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99382967,0.002069278,0.000637064,0.0009274594,0.001889591,0.0006470633],"domain_scores_gemma":[0.9837351,0.0069909496,0.001615623,0.00075517804,0.0031382712,0.0037648787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008427338,0.0006534739,0.0016610752,0.0017472351,0.0028009084,0.010090426,0.0018920674,0.00794582,0.011091558],"category_scores_gemma":[0.017090691,0.00052936166,0.0007934735,0.0024931286,0.007860257,0.017469587,0.0046986486,0.018681591,0.0033140364],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032292918,0.00019043857,0.0076376493,0.00228463,0.00018281631,0.001036423,0.005253777,0.0005218147,0.00067247637,0.063755974,0.5051362,0.41300482],"study_design_scores_gemma":[0.000028726128,0.00016088645,0.008283171,0.0048163487,0.000050594714,0.001827216,0.009338981,0.00026798775,0.00017130145,0.077650696,0.8972821,0.00012191901],"about_ca_topic_score_codex":0.008697506,"about_ca_topic_score_gemma":0.015250539,"teacher_disagreement_score":0.011091558,"about_ca_system_score_codex":0.0049046236,"about_ca_system_score_gemma":0.006742189,"threshold_uncertainty_score":0.04456854},"labels":[],"label_agreement":null},{"id":"W4387369486","doi":"10.33590/emjcardiol/10005818","title":"Obstructive Sleep Apnoea as an Exacerbator of Vasospastic Angina","year":2023,"lang":"en","type":"article","venue":"EMJ Cardiology","topic":"Obstructive Sleep Apnea Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North; NOSM University","funders":"","keywords":"Vasospastic angina; Medicine; Angina; Continuous positive airway pressure; Sleep (system call); Cardiology; Internal medicine; Calcium channel blocker; Airway; Anesthesia; Blood pressure; Obstructive sleep apnea","score_opus":0.024230341545517318,"score_gpt":0.32274593992635214,"score_spread":0.2985155983808348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387369486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716333,0.017486246,0.00036539626,0.0012585426,0.0001438445,0.0000464019,0.0000587469,0.000039594717,0.008967863],"genre_scores_gemma":[0.9946866,0.0035921342,0.00015342578,0.00029764237,0.0007226673,0.0000060859857,0.0000439433,0.0000037666412,0.0004936931],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99964833,0.00009784675,0.00004640229,0.000039488332,0.00006574824,0.00010220842],"domain_scores_gemma":[0.9986349,0.00055221445,0.00045143903,0.00006533423,0.00007131368,0.0002248004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037556462,0.0004417837,0.00044743487,0.001019028,0.0005302353,0.00062213116,0.0003085648,0.0012567539,0.0027314813],"category_scores_gemma":[0.0020666195,0.00031311842,0.0003837596,0.0005458221,0.00056917337,0.00067636225,0.000511245,0.0008149236,0.00031074052],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045173746,0.000100300014,0.38631144,0.00023944132,0.000058579524,0.5938774,0.00077238114,0.000077819735,0.003270998,0.0005245301,0.00074561645,0.013569746],"study_design_scores_gemma":[0.000051088417,0.00040966042,0.35947627,0.00014925758,0.000098527526,0.6347806,0.0008253619,0.00030571187,0.0004426293,0.0004464618,0.0029840702,0.000030303485],"about_ca_topic_score_codex":0.00060185086,"about_ca_topic_score_gemma":0.0009858913,"teacher_disagreement_score":0.0027314813,"about_ca_system_score_codex":0.00017807254,"about_ca_system_score_gemma":0.00027178435,"threshold_uncertainty_score":0.00913769},"labels":[],"label_agreement":null},{"id":"W4403611890","doi":"10.33590/emjcardiol/jjbl7143","title":"Factor XI/XIa Inhibitors: What We Now Know","year":2024,"lang":"en","type":"article","venue":"EMJ Cardiology","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Anthos Therapeutics","keywords":"Factor (programming language); History; Computer science; Programming language","score_opus":0.02047822475857303,"score_gpt":0.28837775241951774,"score_spread":0.2678995276609447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403611890","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022468992,0.91303205,0.00036330803,0.07204718,0.012145806,0.000008664166,0.0001449428,0.00005089742,0.0019824354],"genre_scores_gemma":[0.0018380728,0.91190284,0.0006282466,0.05758385,0.02632437,0.000021171527,0.00018780123,0.000015384396,0.0014982475],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981243,0.00039950674,0.0002739218,0.00030955832,0.0006598371,0.00023283473],"domain_scores_gemma":[0.9829016,0.009040869,0.0013277866,0.0006306469,0.0034020913,0.002697108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049168966,0.0011769056,0.003417682,0.0018493738,0.001170292,0.0070406487,0.0019238245,0.007426833,0.013338282],"category_scores_gemma":[0.014001896,0.00059064256,0.0013703862,0.0020799588,0.0032104878,0.013523354,0.0017286176,0.014241806,0.007064909],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030396323,0.00020964454,0.00081338885,0.00854829,0.00017137553,0.00044082126,0.00025299596,0.00022720355,0.0006839577,0.005663086,0.492313,0.49037236],"study_design_scores_gemma":[0.000049327413,0.00014625881,0.00082137284,0.0061246855,0.0001024848,0.000988883,0.00042444994,0.00010498241,0.00015186206,0.009949618,0.98107713,0.00005889755],"about_ca_topic_score_codex":0.0022409332,"about_ca_topic_score_gemma":0.0029966575,"teacher_disagreement_score":0.013338282,"about_ca_system_score_codex":0.0015620607,"about_ca_system_score_gemma":0.004565156,"threshold_uncertainty_score":0.04462093},"labels":[],"label_agreement":null},{"id":"W4414981228","doi":"10.33590/emjcardiol/nhqg4714","title":"Preoperative Baseline Troponin as a Predictor of Major Adverse Cardiac Events Following Kidney Transplantation in Patients with End-Stage Kidney Disease","year":2025,"lang":"en","type":"article","venue":"EMJ Cardiology","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Kidney disease; Kidney transplantation; Troponin; Adverse effect; Kidney transplant; Kidney; Troponin T","score_opus":0.004246754295885975,"score_gpt":0.24450868311242843,"score_spread":0.24026192881654246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414981228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99908507,0.00026408522,0.00005455926,0.00009828284,0.000028841667,0.000002868885,0.00006425281,0.0000016549199,0.00040025986],"genre_scores_gemma":[0.99954045,0.00010578151,0.00004533671,0.000045970846,0.000042492695,0.0000023071382,0.00012728572,7.139217e-7,0.00008964308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995864,0.00009707309,0.00006180736,0.000055277622,0.00007482929,0.00012453868],"domain_scores_gemma":[0.99818665,0.00047229344,0.00059354596,0.000058766545,0.000109015666,0.0005797069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057119183,0.00025291656,0.00046156315,0.000423006,0.00041704497,0.0009648073,0.0003283012,0.0007193602,0.0014438418],"category_scores_gemma":[0.00274688,0.00019827038,0.0006561561,0.0006191995,0.00041492717,0.0006205214,0.00052905595,0.0012891344,0.00013549106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026988363,0.00006398748,0.9984212,0.000008058573,0.000046296736,0.0000849344,0.00002621517,0.000052939842,0.00014021595,0.00002915958,0.000058297283,0.0007988015],"study_design_scores_gemma":[0.000010483107,0.00016145923,0.99888164,0.000008380929,0.00004711547,0.00019034983,0.00016213507,0.0003491746,0.000046995337,0.00006414154,0.00007240073,0.0000057341545],"about_ca_topic_score_codex":0.0018369622,"about_ca_topic_score_gemma":0.0034066106,"teacher_disagreement_score":0.0018369622,"about_ca_system_score_codex":0.00034598337,"about_ca_system_score_gemma":0.0007739478,"threshold_uncertainty_score":0.004830122},"labels":[],"label_agreement":null}]}